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Abstract: Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide, and the inci-
dence of this fatal disease is still on rise. The majority of HCCs emerge in the background of a chronic liver disease, such 
as chronic hepatitis and liver cirrhosis. The current understanding is that majority of HCCs evolve as a consequence of 
chronic inflammation and due to the presence of infection with hepatitis viruses. These underlying pathogenic stimuli sub-
sequently induce a spectrum of genetic and epigenetic alterations in several cancer-related genes, which are involved in 
cell-cycle regulation, cell growth and adhesion. Such widespread genomic alterations cause disruption of normal cellular 
signaling and finally lead to the acquisition of a malignant phenotype in HCC. In general, the type of gene alterations, 
such as point mutations, deletion of chromosomal regions and abnormal methylation of gene promoters differ according to 
the individual targeted gene. In HCC, incidence of genetic alterations is relatively rare and is limited to a subset of few 
cancer-specific genes, such as the tumor suppressor p53, RB genes and oncogenes such as the CTNNB1. In contrast, epi-
genetic changes that involve aberrant methylation of genes and other post-transcriptional histone modifications occur far 
more frequently, and some of these epigenetic alterations are now being exploited for the development of molecular diag-
nostic signatures for HCC. In addition, recent findings of unique microRNA expression profiles also provide an evidence 
for the existence of novel mechanisms for gene expression regulation in HCC. In this review article, we will review the 
current state of knowledge on the activation of various oncogenic pathways and the inactivation of tumor suppressor 
pathways in HCC that result in the disruption of cancer-related gene function. In addition, we will specifically emphasize 
the clinical implication of some of these genetic and epigenetic alterations in the management of hepatocarcinogenesis. 
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INTRODUCTION 
  It is now widely accepted that stepwise accumulation of 
mutations in cancer-related genes and chromosomal altera-
tions are involved in human carcinogenesis [1]. However, in 
the last decade we have recognized that in addition to genetic 
artifacts, epigenetic alterations that involve aberrant methyla-
tion of gene promoters and dysregulated expression of mi-
croRNA (miRNA), constitute equally important mechanisms 
of genomic instability in human cancers. Studies of these 
molecular alterations in hepatocellular carcinoma (HCC) 
have also revealed that this malignancy involves a multi-
pathway process, and accumulation of genetic and epigenetic 
events leads to an abnormal activation or inactivation of 
multiple cellular signaling pathways including cellular pro-
liferation, cellular survival, differentiation, and angiogenesis. 
Additionally, the emerging consensus is that the core bio-
logical processes including regulation of p53/ARF, 
RB/INK4A and Wnt/-catenin pathways are commonly   
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affected in a majority of HCCs regardless of the etiologies, 
suggesting the presence of a common oncogenic process of 
HCC development.  
  This review provides an overview of genetic and epige-
netic alterations observed in HCC, and discusses how these 
abnormalities relate to the disruption of specific biological 
signaling for the maintenance of homeostasis in normal he-
patocytes. It is anticipated that such precise analyses of ge-
nomic profiling will reveal a global scheme of molecular 
classification of HCC, aid in the development of novel mo-
lecular-targeted therapy for specific subclasses of HCC, as 
well as assist once in the discovery and development of di-
agnostic and predictive biomarkers of HCC. 
P53/ARF PATHWAY 
  The p53/ARF pathway plays a key role in a variety of 
cellular functions, such as regulation of cell cycle, apoptosis 
and DNA repair. Cellular stress activates this pathway by 
activating the p53 protein as a transcription factor, and leads 
to the induction of the transcriptional network of p53- 
responsive genes [2]. The p53 circuit communicates with 
several fundamental cellular signals, such as the Wnt/- 
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p53 protein has a variety of important functions for the main- 
tenance of cellular responses, disruption of the p53/ARF 
pathway has been reported in almost every type of cancer 
including hepatocellular carcinoma (HCC) [3]. Notwith- 
standing the existence of multiple auto-regulatory loops that 
control p53 activity, MDM2 protein plays a central role in 
this process. The ARF antagonizes functions of MDM2 to 
induce regulatory responses that depend on the activation of 
p53 and its target genes. Although disruption of the p53 oc- 
curs in a subset of HCC, more than half of tumors retain a 
wild-type p53, suggesting that alteration of other molecules 
involved in this pathway might also contribute to hepatocar-
cinogenesis [4]. 
The p53 Gene 
 The  p53 gene is located on 17p13.1 and encodes this 
transcription factor with a tumor suppressor function. In hu-
man HCC, common alterations of the p53 gene are point 
mutations within the conserved region of exons accompanied 
by loss of the short arm of chromosome 17. Generally, 30 - 
60% of HCC carry mutations of the p53 gene [3]. The spec-
trum of point mutations reported in HCC varies according to 
the etiology of the underlying molecular pathogenesis. For 
example, aflatoxin B1 (AFB1) reportedly induces G:C to 
T:A transversion mutation in codon 249 of the p53 [5, 6]. As 
this type of mutation is detected in serum of HCC patients 
with an exposure to AFB1, this can be applied for risk as-
sessment of HCC, and as a potential biomarker of HCC 
emergence and exposure to AFB1 [7]. However, it has been 
shown that AFB1-related liver tumor in rats didn’t carry any 
specific mutations that corresponded to codon 249 of human 
HCC [8]. On the other hand, transgenic mice with the hepati-
tis B virus-X (HBx) gene, in concert with AFB1 intake, de-
velop HCC harboring G:C to T:A transversion mutation at 
the site corresponding to the codon 249 of the human p53 
[9]. This evidence highlights the potential scenario where 
both AFB1 insult and infection with HBV are required for 
the evolution of specific mutations within the p53 gene in 
HCC. 
  On the other hand, even though the mutational spectrum 
of the p53 gene in AFB1-negative HCC is heterogeneous, 
the majority of mutations are still confined to a conserved 
region of DNA-binding domain encoded on exons 5 – 9 [4].  
  Other reports suggest that viral proteins affect the func-
tion of the p53 protein and contribute to HCC formation. For 
example, HBx protein itself reportedly binds to p53 and dis-
turbs its capacity for DNA binding, transcription and induc-
tion of apoptosis [10]. None of the previous reports have 
provided any evidence for the direct action of HCV-related 
protein to p53. However, it has been shown that, nitric oxide 
(NO), which is induced by inflammatory cytokines such as 
TNF- and IFN- in chronic hepatitis C virus (HCV) infec-
tion, can induce mutation of cancer-related genes including 
the p53. In cases of colon cancer and lung cancer, nitric ox-
ide synthetase 2 activity in the tumor closely related to the 
G:C to A:T mutations in the p53 gene within the CpG sites 
[11], which is the major type of mutation in the p53 gene 
found in HCC without AFB1 contamination.  
The CDKN2A (p14
ARF) Gene 
 The  CDKN2A gene encodes two tumor suppressors, 
p14
ARF and p16
INK4a, which share the same second exons. 
The p14
ARF transcript functions as a stabilizer of the p53 
protein. The p14
ARF interacts with the MDM2 protein, which 
is responsible for the degradation of p53 and in regulating 
the control of cell cycle during G1-S phase [12]. This gene is 
frequently mutated or deleted in a wide variety of human 
tumors including HCC. Generally, 7% of HCC carry homo-
zygous deletion of the CDKN2A gene, and inactivation of the 
p14
ARF gene via aberrant methylation its gene promoter is a 
frequent event in HCC [13]. However, according to our 
analysis, methylation of the promoter of p14
ARF was also 
evident in small proportion of non-cancerous liver tissues as 
well, but it was far more frequent in HCC tissues [14]. In 
addition, a decrease of mRNA level was detected exclusively 
in HCC with homozygous deletion of this gene. From this 
point of view, the role of methylation at the promoter of 
p14
ARF may still be viewed somewhat controversial in patho-
genesis of HCC [14]. 
The CDKN1A and CDKA1B Genes 
  Although alterations in the genomic sequences of the 
tumor suppressor CDKN1A and CDKN1B genes are rare in 
HCC, the down-regulation of these cell-cycle regulatory pro-
teins has been frequently reported [15-17]. Expression of 
p21
WAF1, the product of the CDKN1A gene, is regulated by 
the tumor suppressor p53, and p21
WAF1 in turn regulates the 
activities of cyclin-dependent kinases (CDK) 2 and 4, which 
control the G1-S and G2-M phase of cell cycle, respectively. 
In human HCC, down-regulation of p21
WAF1  has been ob-
served and it associates with tumor progression and bad 
prognosis of the disease [15]. The virus-related protein of 
HBx and core protein of HCV are also known to suppress 
transcription of p21
WAF1 [16]. 
 P27
kip1, the product of the CDKN1B gene, is also a mem-
ber of cyclin dependent kinase inhibitors (CDKI) and inhib-
its kinase activity of cyclin E-CDK2 and cyclin D-CDK4. 
The expression level of this CDKI was also correlated to the 
poor outcomes for disease-free survival of HCC cases [17]. 
The protein level of p27
kip1 was reportedly lower in cirrhotic 
liver of non-cancerous tissues of HCC cases than in those 
without HCC, and the down-regulation of its expression was 
associated with promoter methylation of the CDKN1B gene 
[17, 18]. 
RB/INK4A PATHWAY 
  The RB/INK4A pathway plays a central role in the regu-
lation of the G1-S phase of cell cycle progression. It is 
known that RB activities associate with its phosphorylation 
status, and phosphorylation of RB depends on cell cycle pro-
gression coupled with the activation of CDK. The un-
phosphlyrated RB binds to the E2F-1 transcription factor, 
preventing it from interacting with the transcriptional ma-
chinery within the cell. The phosphorylated RB sequesters 
E2Fs, which are responsible for the transcription of many 
genes [19]. Among these genes, cyclin E, which binds to the 
CDK2, induces DNA replication during cell cycle. The ma-
jority of tumors, including HCC, frequently harbor aberra-
tions of the members of this pathway. Our analyses indicate 132    Current Genomics, 2011, Vol. 12, No. 2  Nishida and Goel 
that 81% of HCC showed alteration of at least one compo-
nent of the RB/INK4A pathway [20-22].  
The RB Gene 
  Loss of RB activity has been identified in many types of 
cancers including retinoblastoma, osteosarcomas, small cell 
and non-small cell lung cancers, breast cancer and HCC. In 
human HCC, 18–48% of tumors represent chromosomal loss 
of 13q14 region, where the RB gene resides. Our previous 
reports demonstrate that some HCCs with loss of heterozy-
gosity on 13q14 carry additional structural alterations of the 
interstitial deletion in the RB gene, suggesting that a double 
hit on this locus leads to complete functional inactivation of 
RB [23]. On the other hand, down-regulation of RB protein 
is observed in 30–50% of HCC tissues compared to their 
corresponding non-neoplastic liver tissues [24]. Although the 
precise mechanism of the down-regulation of RB has not 
been clarified completely, some reports have suggested that 
abnormal methylation of the RB promoter may cause tran-
scriptional inactivation of the gene in cancer cells [25]. 
The CDKN2A (p16
INK4a ) Gene 
  As described previously, p16
INK4a is a tumor suppressor 
protein, which is encoded by the CDKN2A gene. This mole-
cule plays an important role in regulating the cell cycle, by 
inhibiting CDK4 and controlling cell cycle progression at the 
G1 phase. Mutation of p16
INK4a is also involved in the devel-
opment of a variety of cancers including HCC.  
  Some HCCs carry homozygous deletions or point muta-
tions of p16
INK4a [26]. However, recent data suggests that the 
major mechanism of inactivation of this gene is abnormal 
methylation of its gene promoter. As much as 40-70% of 
HCCs demonstrate p16
INK4a methylation, and this aberrant 
methylation associates with the down-regulation of the pro-
tein expression [27]. Since low-levels of methylation were 
also detected in the background non-cancerous liver of the 
HCC patients, we normalized methylation levels in HCC 
tissues to the background aberrant methylation and deter-
mined that p16
INK4a methylation inactivates the gene in 63% 
of human HCC cases (Fig. 1) [28]. Previous reports suggest 
that p16
INK4a methylation also associates with the presence of 
HBV or HCV infection [29].  
  As described above, there is a close association between 
RB/INK4A pathway and p53/ARF pathway, especially in the 
regulation of cell cycle progression and apoptosis. We sum-
marized the association of the responsible molecules in these 
pathways and the type of their alterations found in HCC in 
Fig. (2). 
WNT/-CATENIN PATHWAY 
  Activation of Wnt/-catenin pathway facilitates the ex-
pression of several genes indispensable for cell growth, such 
as c-myc and cyclin D1, through translocation of -catenin 
to nucleus and its interaction with various transcription   
factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Mean methylation levels and frequencies of hypermethylation of several tumor suppressor genes (TSGs) in HCC. In contrast to 
genetic alterations such as point mutation, a variety of TSGs are frequently inactivated via epigenetic mechanism, suggesting that DNA 
methylation is a major alteration as a driver for human hepatocarcinogenesis.  
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 In  general,  -catenin within cells is present in the form of 
complexes with several proteins, and the ability of -catenin 
to bind to other proteins is regulated by tyrosine kinases and 
serine kinases, such as glycogen synthase kinase (GSK)-3. 
The binding proteins include cell adhesion molecules, sev-
eral transcription factors, and axin, which is a component of 
the Wnt signalling pathway. -catenin is associated with the 
axin complex together with GSK-3 and APC (adenomatosis 
polyposis coli) [30, 31]. This complex substantially induces 
the increase in phosphorylation of -catenin by facilitating 
the action of GSK-3, which leads to ubiquitin-dependent 
degradation of -catenin by proteosomes. The action of 
GSK-3 is inhibited by the binding of Wnt to its receptors, 
which leads to the translocation of -catenin to the nucleus 
and induction of a variety of functions within this pathway 
[32]. -catenin also acts in conjunction with the T-cell factor 
(TCF)/lymphoid enhancing factor (LEF) family transcription 
factors to activate several target genes.  
  Among the components of the Wnt/-catenin pathway, 
the APC gene is known to be the primary target in patients 
with familial adenomatous polyposis (FAP) colon cancers 
[33]. Similarly, mutation of the AXIN2 is a cause of attenu-
ated polyposis [34], and mutation of the CDH1 gene is 
known to induce familial gastric cancer [35]. Alterations of 
several components of this pathway are also common events 
in human HCC (Fig. 3). 
The CTNNB1 Gene 
  -catenin is encoded by the CTNNB1 gene and plays an 
important role in various aspects of liver biology including 
pathogenesis of liver cancer. Mutations in this gene are the 
cause of several cancers, such as colorectal cancer and ovar-
ian cancer [36, 37]. In human HCC, point mutations or dele-
tions at the phosphorylation site on neighboring codons in 
the exon 3 of the CTNNB1 have been proposed to cause de-
regulation of the signaling function and contribute towards 
HCC pathogenesis. Generally speaking, 10–30 % of HCC 
carries mutations of the CTNNB1 gene, which induces the 
accumulation of -catenin in the nucleus [28].  
The AXIN Genes 
  As described above, the axin protein interacts with APC, 
-catenin, GSK-3, and protein phosphate 2. Mutations in 
this gene are also associated with hepatocellular carcinoma, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic representation of alterations in p53/ARF and RB/INK4A pathways in HCC. Molecules with oncogenic function are 
shown in yellow and those with tumor suppressive function are shown in blue. Specific type of genetic and epigenetic alterations found in 
HCC are shown in red letter. 
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hepatoblastomas, and several other cancers. Mutations of the 
AXIN1 gene can be detected in 5–9 %, and mutations of the 
AXIN2 are reported in ~3% of human HCC or HCC cell lines 
that carry the wild type CTNNB1 gene [38]. Gene transfer of 
wild-type AXIN1 resulted in enhanced apoptosis in HCC cell 
lines as a consequence of increased accumulation of -
catenin in the nucleus. On the other hand, some target genes 
of -catenin, such as glutamine synthetase, did not show an 
enhanced expression even in cell lines with the mutated 
AXIN genes, suggesting that the tumor suppressor function 
of this protein might act via additional pathways other than 
Wnt/-catenin [39]. 
The APC Gene 
  APC also forms complexes with axin and GSK-3 , and 
contributes in controlling cellular -catenin levels through 
ubiquitin proteasome-dependent degradation of -catenin. In 
human HCC, biallelic inactivation of the APC gene (muta-
tion of the gene accompanied by loss of chromosomal region 
of the APC locus) was reported in a HCC case [40]. In our 
analysis, 84% of HCC carried dense methylation on the 
promoter of this gene in HCC (Fig. 1), indicating that pro-
moter methylation was the major mechanism of inactivation 
of the APC gene in human HCC [28].
 
The CDH1 (E-Cadherin) Gene 
  E-cadherin is a calcium-dependent cell-cell adhesion 
glycoprotein that plays an important role in the formation of 
the epithelial cell layer. Cadherin can be found in complexes 
with catenin, which is important for the biological function 
of this gene. The oncogenic signals from EGF and Src also 
target -catenin. It has been shown that phosphorylation of 
-catenin through the EGF pathway associated with invasion 
and metastasis of cancer because of suppression of the adhe-
sion function of Cadherin [41]. Mutations of this gene are 
reported in gastric, colorectal and breast cancers. Loss of 
function of this gene contributes to the progression of HCC 
by permitting increased proliferation, invasion, and metasta-
sis of the neoplastic cells. Expression analysis of E-cadherin 
in hepatocellular carcinomas demonstrated that 56% of HCC 
showed the down-regulation of E-cadherin expression, and 
this phenomenon directly correlated with the size of tumors, 
as well as the mitotic index and survival [42].  
  Several reports suggested that the CDH1 gene can also be 
inactivated through the promoter hypermethylation of its 
promoter region. Interestingly, it has also been reported that 
reactive oxygen species (ROS) induce hypermethylation of 
the  CDH1promoter. In this context, activation of 
PI3K/Akt/GSK-3 by ROS has been shown to recruitment of 
histone deacethylase and DNA methyltransferase on its pro-
moter, which causes the downregulation of CDH1expression 
[43]. Because longstanding chronic inflammation enhances 
the production of ROS in the background liver of HCC, it is 
reasonable to speculate that these epimutations play an im-
portant role in the initial steps of inflammation-related hepa-
tocarcinogenesis. 
Secreted Frizzled-Related Protein (SFRP) 2  
  Frizzled are membrane proteins which are known as re-
ceptors of Wnt. SFRPs act as soluble modulators of Wnt 
signaling as SFRPs containing the putative Wnt-binding site 
of frizzled proteins. Because SFRPs are able to down-
regulate Wnt signaling by forming an inhibitory complex 
with the frizzled receptors, SFRPs are considered as tumor 
suppressors. We have reported that one of the SFRP family 
genes, SFRP2, showed hypermethylation of its promoter and 
was frequently inactivated in human HCC (Fig. 1) [28]. 
ABNORMAL METHYLATION OF TUMOR SUP-
PRESSOR GENES 
  It is now increasingly being recognized that the patterns 
of DNA methylation, which are ordinarily maintained during 
normal cell division, are often disturbed in many human tu-
mors, including HCC. Since low levels of DNA methylation 
can also be detected in the non-cancerous liver of patients 
with chronic liver damage or HCC, it is now believed that 
this epigenetic defect emerges at an early stage during hepa-
tocarcinogenesis [44]. In human HCC, both regional hyper-
methylation of tumor suppressor gene (TSG) promoters and 
hypomethylation of repetitive DNA sequences are com-
monly observed [45]. The former is an important mechanism 
for the inactivation of corresponding gene, while the latter 
  
 
 
Fig. (3). Schematic representation of Wnt/-catenin pathway and 
the alterations reported in HCC. Functions of molecules shown in 
yellow and blue represent oncogenic and tumor suppressive respec-
tively. Specific types of genetic and epigenetic alterations found in 
HCC are shown in red letter.  
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plays a role in maintaining chromosomal fragility and activa-
tion of retrotransposons and microRNA (miRNA), both of 
which could be critical for HCC development and progres-
sion. Although the precise mechanisms for the alteration of 
DNA methylation during hepatocarcinogenesis are still un-
clear, both HBx and HCV core proteins have been shown to 
induce the expression of DNA methyltransferases, which 
then leads to abnormal methylation of the CDH1 gene [46, 
47].  
  We have previously reported that DNA methylation of 
TSGs was closely associated with the presence of HCV not 
only in HCCs but also in chronic hepatitis tissues, suggesting 
that the chronic inflammation or presence of HCV may con-
tribute to the emergence of abnormal methylation [48]. The 
numbers and frequencies of genetic alterations of cancer-
related genes in HCC are limited, however, epigenetic altera-
tions are frequently observed in several TSGs (Fig. 1) [49]. 
CLINICAL IMPLICATIONS OF GENETIC AND EPI-
GENETIC ALTERATIONS 
  Cancer specific alterations of several genes are promising 
candidates for developing molecular markers of HCC, such 
as diagnosis and prediction of prognosis. Among them, al-
teration of DNA methylation is widely and frequently ob-
served in almost every HCC, and DNA methylation can be 
easily and quantitatively measured in a variety of clinical 
specimens. Detection of methylation of the CDKN2A and 
GSTP1 genes in serum has been used for the early diagnosis 
of HCC [50, 51]. Furthermore, detection of the methylated 
CDKN2A and RASSF1A genes in serum of cases at a high 
risk of HCC could predict early occurrence of HCC [52]. 
Similarly, alteration of certain cancer-related genes or onco-
genic pathways could be a target of developing a novel ther-
apy of HCC. For example, a high level of copy-number gain 
and overexpression of vascular endothelial growth factor A 
was reported in a subset of HCC, suggesting that antiangio-
genic therapies could be exclusively effective for this type of 
tumor [53]. 
ALTERED EXPRESSION OF miRNAs 
  Expression of miRNAs, which has been identified as a 
new class of small non-coding family of genes that are in-
volved in post-transcriptional gene regulation, is also shown 
to be frequently altered in HCC. Several comprehensive 
analyses of miRNA have identified differentially expressed 
miRNAs in various subsets of HCCs. This type of alteration 
can also modulate several important signaling pathways, 
which is critical for hepatocarcinogenesis.  
  In human HCCs, miRNA (miR)-122 expression is sig-
nificantly reduced in a subset of HCC compared to the non-
cancerous tissues [54]. miR-122 can modulate cyclin G1 
expression in HCC-derived cell lines, and an inverse correla-
tion between miR-122 and cyclin G1 expression has been 
shown in human HCC, suggesting that cyclin G1 is a target 
of miR-122 [55]. On the other hand, miR-221 also targets 
cell-cycle inhibitors CDKN1B (p27
kip1) and CDKN1C 
(p57
kip2) and its altered expression also results in a disturbed 
normal cell-cycle regulation in hepatocytes [56].  
  MiR-21 is shown to be overexpressed in HCC as well as 
HCC cell lines, and inhibition of miR-21 increases expres-
sion of the tumor suppressor PTEN which helps in decreased 
tumor proliferation and invasion [57]. On the other hand, Ji, 
et al. showed that tumors with reduced miR-26 expression 
had a distinct transcriptomic pattern, with the activation of 
NF-B and IL-6 signaling pathways [58]. Interestingly, in-
duction of IL-6 is reported as an important step for inflam-
mation-related HCC pathogenesis [59], and high levels of 
serum IL-6 can be a risk factor for HCC in HCV-positive 
patients [60]. Activation of this pathway also accounts for 
the gender differences and risk of HCC, as estrogen is 
known to suppress MyD88-dependent IL-6 production, and 
miR-26 is expressed at a higher level in women than men in 
the liver [58, 59]. Reportedly, this miRNA is also a good 
candidate for therapeutic target of HCC. Patients whose tu-
mors had low miR-26 expression had shorter survival but a 
better response to interferon therapy than did patients whose 
tumors had high expression of this miRNA [58]. In addition, 
Kota,  et al. reported the significance of this miRNA on 
treatment response using a mouse model [61]. Expression of 
miR-26 in liver cancer cells in vitro induces cell cycle arrest 
via suppression of cyclin D2 and cyclin E2, and systemic 
administration of miR-26 in mouse HCC model induces in-
hibition of cancer cell proliferation and induction of tumor-
specific apoptosis without toxicity [61]. However, as indi-
vidual miRNAs regulate hundreds of transcripts, antiprolif-
erative effects of miR-26 in HCC, might not attribute to a 
single oncogeneic pathway but a regulation of multiple 
pathways, such as c-Myc and p53-dependent pathway. 
  On the other hand, several other studies revealed the as-
sociation between expression profile of miRNA and etiology 
as well as specific genetic alterations. The miR-96 is overex-
pressed in HBV-related tumors, and miR-126 is down-
regulated in alcohol-related hepatocellular carcinoma. Simi-
larly, several reports suggest that the expression profile of 
miRNA can be applied to evaluate the etiology of tumor and 
predict tumor behavior, such as metastasis and prognosis 
[58, 62-66]. These evidences support the idea that in addition 
to genetic and epigenetic alteration of oncogenes and TSGs, 
the altered expression of miRNAs is an additional mecha-
nism critical for human hepatocarcinogenesis. This concept 
is bound to receive a lot of attention in the coming years, as 
it not only helps in a better understanding of the molecular 
mechanisms of HCC, but also has a potential for clinical use 
including the development of biomarkers and therapeutic 
targets of this malignancy.  
CONCLUSION 
  We have summarized in this review article the spectrum 
of various genetic and epigenetic alterations in a variety of 
genes and their corresponding oncogeneic pathways that are 
operational in human hepatocarcinogenesis (Figs. 2 and 3). 
What we now understand is that similar to many other can-
cers, development of HCC associates with a step-wise 
accumulation of genetic and epigenetic defects in cancer-
related genes that includes point mutations, chromosomal 
alterations, aberrant DNA methylation and alterations of 
miRNA expression. Although the precise underpinnings of 
these various processes are still hazy, nonetheless, it is very 
likely that the defects in multiple signaling pathways might 
overlap and crosstalk exists among these pathways, as the 
premalignant clones progress towards a more advanced stage 
of HCC. Given the high prevalence of chronic liver disease 136    Current Genomics, 2011, Vol. 12, No. 2  Nishida and Goel 
Given the high prevalence of chronic liver disease and HCC 
patients, knowledge of these molecular events is very excit-
ing and timely, because an understanding of these events will 
help tailor approaches that can be best exploited for the early 
detection, management and therapy of HCC. 
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